Duality is thrilled to announce the granting of a license for its DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program. This collaboration is based on the synergies between Adcendo and Duality for creating breakthrough ADCs in hard-to-treat cancers, thus highlighting the validation and recognition of Duality’s ADC technology platform. As part of the agreement, Duality will receive upfront payments, development, regulatory and commercial milestones, and tiered royalties.
Duality Biologics, a clinical-stage biotech company focused on discovering and developing ADCs targeting cancer and autoimmune diseases, has struck a deal with Adcendo ApS. Under the terms of the agreement, Adcendo will be granted the license to Duality’s proprietary DITAC platform, which has been designed to create ADCs with enhanced safety features, efficient delivery of payloads and release in tumors, and effective bystander killing of antigen low and negative cells, for its lead uPARAP-ADC program in mesenchymal cancers. The two organizations are discussing the potential to extend the license to cover additional targets selected by Adcendo.
John Zhu, CEO of Duality, expressed his enthusiasm for the mutual recognition between Duality and Adcendo, two leading next-generation ADC companies. Zhu noted the encouraging initial efficacy and safety results of Duality’s DITAC platform, and expressed his excitement for the collaboration in developing innovative ADC drugs, stating, “We look forward to supporting Adcendo with the global development of these groundbreaking medicines.”
Adcendo CEO Michael Pehl is thrilled to be teaming up with Duality to create cutting-edge ADCs to tackle hard-to-treat cancers. He believes that Duality’s DITAC platform has taken linker-payload technologies to the next level, and he is confident that the collaboration between the two companies will yield treatments with remarkable safety and effectiveness for cancer patients.
For further information:
About Duality Biologics
Duality Biologics is a clinical-stage biotech company revolutionizing the treatment of cancers and autoimmune diseases with its innovative pipeline of antibody-drug conjugates (ADCs). Through its proprietary DITAC (Duality Immune Toxin Antibody Conjugates) and DIMAC (Duality Immune Modulating Antibody Conjugates) technologies, Duality is pushing the boundaries of medical research with more than 10 ADCs at clinical and preclinical stages.
About Adcendo ApS
Adcendo ApS is revolutionizing cancer treatment with its groundbreaking antibody-drug conjugates (ADCs). In 2021, the company raised EUR 51 million in its Series A funding round, backed by leading venture firms such as Novo Holdings, Ysios Capital, RA Capital Management, HealthCap and Gilde Healthcare. This investment marks a significant milestone in the fight against cancer, bringing hope to those in underserved communities.